Acquisition Announced
Eli Lilly and Company acquisition of AtaiBeckley
US$2.8bn equity value
Announced 16 Jul 2026 · NASDAQ: ATAI · US$6.75 cash and scrip per share · 40% premium
Advisers
- Target
- AtaiBeckley
- Acquirer
- Eli Lilly and Company
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Drug Development, Behavioral Health
In the league tables
- M&A financial advisers, 2026 to date Goldman Sachs #2 · Centerview Partners #5 · Citi #7 · Moelis & Company #15
- M&A legal advisers, 2026 to date Latham & Watkins #2 · Sullivan & Cromwell #14 · Ropes & Gray #25 · Cooley #28
- Fairness opinion providers, 2026 to date Centerview Partners #4 · Moelis & Company #7
Similar deals
- Eli Lilly and Company acquisition of AttaiBeckley 2026 · US$3.8bn · Biotech
- Eli Lilly and Company acquisition of Merida Biosciences Aug 2026 · US$2.9bn · Biotech
- Gilead Sciences acquisition of Tubulis Apr 2026 · US$3.1bn · Biotech
- GSK acquisition of RAPT Therapeutics Jan 2026 · US$2.2bn · Biotech
- Eli Lilly and Company acquisition of Ajax Therapeutics Apr 2026 · US$2.3bn · Biotech
Sources
- 2026 Centerview Partners: Centerview as Financial Advisor to AtaiBeckley on its sale to Eli Lilly centerviewpartners.com
- Jul 2026 Latham Represents AtaiBeckley in Sale to Lilly lw.com
- 16 Jul 2026 Press release (EX-99.1, exhibit), Jessica Bardoulas; jessica.bardoulas@lilly.com; (Media) sec.gov
- 16 Jul 2026 Lilly to Acquire AtaiBeckley cooley.com
- 16 Jul 2026 Press release (PR Newswire), Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions prnewswire.com
- 17 Jul 2026 S&C Advises Investor Apeiron on AtaiBeckley’s Acquisition by Eli Lilly for Up To $3.8 Billion sullcrom.com
- 10 Aug 2026 Definitive merger proxy statement (DEFM14A), AtaiBeckley Inc. sec.gov





